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Abstract
There is limited data on the clinical, cellular and molecular changes in relapsed acute pro-
myeloytic leukemia (RAPL) in comparison with newly diagnosed cases (NAPL). We under-
took a prospective study to compare NAPL and RAPL patients treated with arsenic trioxide
(ATO) based regimens. 98 NAPL and 28 RAPL were enrolled in this study. RAPL patients
had a significantly lower WBC count and higher platelet count at diagnosis. IC bleeds was
significantly lower in RAPL cases (P=0.022). The ability of malignant promyelocytes to con-
centrate ATO intracellularly and their in-vitro IC50 to ATO was not significantly different be-
tween the two groups. Targeted NGS revealed PML B2 domain mutations in 4 (15.38%) of
the RAPL subset and none were associated with secondary resistance to ATO. A microar-
ray GEP revealed 1744 genes were 2 fold and above differentially expressed between the
two groups. The most prominent differentially regulated pathways were cell adhesion
(n=92), cell survival (n=50), immune regulation (n=74) and stem cell regulation (n=51). Con-
sistent with the GEP data, immunophenotyping revealed significantly increased CD34 ex-
pression (P=0.001) in RAPL cases and there was in-vitro evidence of significant
microenvironment mediated innate resistance (EM-DR) to ATO. Resistance and relapse
following treatment with ATO is probably multi-factorial, mutations in PML B2 domain while
seen only in RAPL may not be the major clinically relevant cause of subsequent relapses.
In RAPL additional factors such as expansion of the leukemia initiating compartment
along with EM-DR may contribute significantly to relapse following treatment with ATO
based regimens.
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Introduction
Significant strides have been made in the management of acute promyelocytic leukemia (APL)
in the last two decades[1]. There has been an evolution in the treatment of APL towards re-
duced intensity and low toxicity regimens by the use of targeted therapeutic agents. This was
facilitated by the improved understanding of cellular and molecular biology of this condition
and recognition of mechanism of action of some of the non chemotherapeutic agents used to
treat this condition[2, 3]. Key agents that have contributed to reduced intensity of chemothera-
py have been the use of all-trans retinoic acid (ATRA)[4] and arsenic trioxide (ATO) either
alone or in combination[5, 6]. While there is significant understanding of the mechanisms of
resistance to ATRA[7] there is limited data on the potential mechanisms of resistance to ATO,
especially that which is relevant in the clinic.
The treatment of newly diagnosed APL patients (NAPL) with either single agent ATO or
ATO combined with ATRA has been reported to be associated with durable remissions and
minimal toxicity, with results being comparable to that achieved with conventional chemother-
apy used for this disease[8–10]. Despite its efficacy in the treatment of APL it has been noted
that 10–20% of newly diagnosed and 30–50% of relapsed patients (RAPL) will relapse, mostly
within the high risk subset, after treatment with ATO based regimens[11, 12]. In patients with
RAPL, ATO is effective in inducing molecular remissions in the majority without the toxicity
profile of combination chemotherapy and it does not have cross resistance with ATRA[9, 12].
However, in the absence of consolidation with an autologous stem cell transplantation (SCT)
there is a high incidence of relapse[13]. There is limited data to explain this inferior long term
clinical response in RAPL treated with ATO based regimens in contrast to NAPL.
As with other malignancies, it is likely that patients with RAPL have acquired additional cy-
togenetic, molecular and cellular defects that accounts for these differences which have not
been well characterized[14–16]. Potential mechanisms of relapse in APL treated with ATO
could be related to clonal evolution leading to ATO resistance or resistance in a poorly defined
leukemia initiating compartment. Recently it was recognized that ATO directly binds to the B2
domain of the PML-RARA oncoprotein which leads to its SUMOylation and subsequent deg-
radation [17]. More significantly it was reported that mutations in the same domain leads to re-
sistance to ATO [18]. There is limited data on the frequency of these mutations in a cohort of
patients with RAPL previously treated with ATO. It is also recognized that majority of RAPL
patients do not have any mutations in the PML-RARA gene[19]. The role of microenviron-
ment-mediated drug resistance (EM-DR) in APL treated with ATO is not known.
At our center we have been using a single agent ATO based regimen for NAPL for more
than a decade. We were hence in a unique position to compare NAPL treated with such a regi-
men and compare acquired changes in patients who subsequently relapsed.
Materials and Methods
Patients and Samples
FromMay 2007 to December 2011, bone marrow and peripheral blood samples from NAPL
and RAPL (hematological relapses only) admitted at our center were enrolled in this prospec-
tive study. Institutional review board approved the study design and the consent forms. Writ-
ten and informed consent was obtained from all enrolled cases. (Institutional Review Board of
Christian Medical College, Vellore, India: IRB, CMC, Vellore. RC Min 5884. 18th April, 2006).
NAPL were treated with a single agent ATO based regimen as has been previously reported by
us[11, 20]. The clinical outcome in RAPL consolidated with and without an autologous SCT
following induction of molecular remission has also been previously reported by us[13]. The
Comparison of Newly Diagnosed and Relapsed APL Treated with ATO
PLOSONE | DOI:10.1371/journal.pone.0121912 March 30, 2015 2 / 15
additional role in the study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. The specific roles of these authors are
articulated in the ‘author contributions’ section.
Competing Interests: Three of the authors (MA, NM
and RM) are employed by Genotypic Technologies,
Bengaluru. This does not alter the authors' adherence
to PLOS ONE policies on sharing data and materials.
There are no restrictions on sharing of data and/or
materials from this study as a result of them being co-
authors on this manuscript.
human APL cell line NB4[21] (Kind gift from Dr Harry Iland, RPAH, Sydney, Australia with
permission from Dr Michel Lanotte) was used for some experiments. HUVEC cell line (ATCC,
Manassas, USA) was used as a control for stromal cells in the co-culture experiments. An ATO
resistance cell line (NB4EV AsR1) was derived from the NB4 cell line in-house and was also
used as a control for some experiments.
Enrichment of Promyelocytes by Lineage Depletion using VarioMACS
Patient samples having<80% blasts were enriched by negative selection using lineage deple-
tion cocktail in a VarioMACS system (MitenyiBiotec, Gladbach, Germany) and were purified
to target90% blasts for experiments, where this was required.
Morphology, immunophenotype (IPT) and cytogenetic (CTG) evaluation
These were done using standard established methods (S1 File Methods A to C).
Intracellular Arsenic trioxide Concentration
The intracellular level of arsenic was measured by atomic absorption spectrometry in the blasts
using well established and published protocols [22, 23]. Details of the method and steps taken
to standardize the assay are provided in the S1 File: Methods D.
In-vitro ATO Cytotoxicity Assay
An in-vitro evaluation of ATO sensitivity was done using an MTT assay system (Biotium, Inc.
CA, USA) (S1 File: Methods E).
Screening for PML mutations using targeted Ion torrent PGM next
generation sequencing (NGS)
Targeted customized exome sequencing was done for PML-RARA transcripts using cDNAs
from 27 NAPL and 25 RAPL cases. Library preparation and Ion PGM sequencing were per-
formed following certified protocols (Life-technologies, Carlsbad, CA, USA) at Genotypic
Technology genomics facility (Bengaluru, India). A two step nested RT-PCR was performed to
amplify B2 domain of the PML transcripts using in house generated primers (S1 File: Methods
F: Details of library preparation, quality assessment steps are also given). The reads were
aligned to the reference PML amplicon using TMAP algorithm and variants were detected by
the plugin Variant caller (v) of Torrent Suite v3.6.2.
Microarray Analysis for Gene Expression Profiling (GEP)
Patients bone marrow samples at diagnosis and at relapse with 90% blasts or enriched sam-
ples were used for microarray studies (Genotypic Technology, Bengaluru). Gene expression
microarray was done using 44k human microarray chip analysis (Agilent technologies)
(S1 File: Methods G).
Validation of microarray data
To validate the results obtained by microarray with an independent method we did real-time
RT-PCR (RQ-PCR) using commercially available ABI TaqMan assay system (Applied Biosys-
tems, Darmstadt, Germany). We randomly chose 25 genes from the differentially regulated list
and assessed their expression levels in the samples from the 8 unmatched newly diagnosed
and relapsed cases on (samples on which the microarray analysis was initially done). We also
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did the RQ-PCR analysis for the same 25 genes in a second validation set of 10 patients for
whom sequential samples at diagnosis and relapse were subsequently available. The expression
levels of the target genes and an endogenous control gene (GAPDH) were evaluated. The rela-
tive expression of these target genes at diagnosis and at relapse was calculated by 2-ΔΔCT meth-
od and expressed as fold difference.
Impact of Stromal Interaction with Malignant Promyelocytes
After getting written informed consent third party mesenchymal stromal cells (MSC) were iso-
lated from an aliquot of bone marrow taken from healthy allogeneic donors. For all experi-
ments MSCs from passages 3 and 4 were used. These experiments were also repeated using a
stromal cell line (HS-5). NB4 cell lines or primary APL cells (1x105cells/well) were added on a
layer of MSCs (at least 70% confluent at time of experiment). The co-culture system was left in
the incubator overnight and then exposed to 2μM, 4μM and 6μMATO concentrations. Appro-
priate controls with and without stromal cells were included. After 48 hour incubation at 37°C
in a CO2 incubator, Annexin V apoptosis assay was performed as per standard and established
immune-phenotyping protocols (The data generated was compared to untreated cells main-
tained for the same period which for standardization was taken as 100%). Further evaluation of
impact of co-culture on cell cycle analysis, cell proliferation assays, changes in the surface
marker expression and the effect of blocking VLA-4 and VLA-5 integrin on the chemosensitiv-
ity was done on NB4 cells. (S1 File: Methods H).
Statistical Analysis
The χ2 or fisher exact test and MannWhitney U test were used to compare differences between
groups for clinical and laboratory parameters. The probability of survival was estimated with
the use of the product-limit method of Kaplan-Meier for overall survival (OS), event free sur-
vival (EFS) was compared by the log rank test. All survival estimates are reported as ± 1SE. All
P-values were 2-sided, with values of 0.05 or less indicating statistical significance. Statistical
analysis used the SPSS 16.0 Software (Chicago, USA). Non linear regression curves were done
with GraphPad Prism Software V5 (California, USA).
Results
Patient accrual and the baseline demographic data
Ninety eight (78%) were NAPL and 28 (22%) were RAPL. Among the 28 RAPL, twenty three
of them were first relapse and 5 were second relapses. Eleven of the 28 relapse cases had
matched samples available at diagnosis. All 28 had relapsed in the bone marrow with a median
blast percentage of 82% (range: 26–98), while 2 cases had additional extra-medullary relapse in
the central nervous system. Table 1 summarizes the clinical comparison between NAPL and
RAPL. Briefly, the median age of NAPL and RAPL cases were not significantly different. The
number of males in the RAPL group was significantly higher. RAPL had a significantly lower
white cell count (P<0.0001) and a significantly higher platelet count (P = 0.006) at the time of
diagnosis in comparison to NAPL. There was less coagulopathy in the RAPL in comparison to
NAPL as evidenced by the significantly lower number of intra-cranial bleeds (P = 0.022) and
the significantly lower number of platelet units utilized during induction therapy (P = 0.027).
The possibility of a lead time bias resulting in earlier diagnosis of relapsed patients (on regular
follow up) compared to newly diagnosed patients resulting in lower white cell counts and coa-
gulopathy cannot be excluded.
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Comparison of cellular and in-vitro ATO sensitivity
Potential morphological distinguishing features between the NAPL and RAPL samples were re-
viewed in 20 random blinded samples from the NAPL and RAPL group by two independent
hemato-pathologists. The consensus was that there were no distinguishing morphological fea-
tures between these two groups.
IPT data was available on 90 NAPL and 20 RAPL cases within our study cohort and these
were evaluated for this analysis. Fig 1 compares the percentage expression of the common APL
markers between NAPL and RAPL. The RAPL had a significantly higher expression of CD34
(P = 0.001) and lower expression of CD13 (P = 0.001) and CD38 (P = 0.040) when compared
to the NAPL (Figure B in S1 File—data as median fluorescent intensity).
The intracellular arsenic levels (ICATO) were measured in 61 NAPL and 19 RAPL. The
ability of both NAPL and RAPL blasts to concentrate ATO intracellular was not significantly
different (Median value: 12.85ng/107 cells vs. 11.78ng/107 cells) (Fig 2). The ICATO values did
not correlate with clinical parameters such as relapse, EFS or OS.
Furthermore in-vitro sensitivity of malignant blasts from APL patients at diagnosis and
relapse to ATO measured by an MTT assay in 61 NAPL and 23RAPL were not significantly
Table 1. Comparison of the clinical and demographic data of the newly diagnosed patients Vs. relapsed acute promyelocytic leukemia patients.
Demographic Parameters Newly Diagnosed N = 98 N (%) / Median
(Range)
Relapsed N = 28 N (%) / Median
(Range)
P-
value
Age (years) 28 (2–60) 31 (8–54) 0.997
Sex: Male 48 (49) 25 (89.3) 0.000
WBC x 109/Lt 14.5 (0.5–290) 3.5 (0.5–24.90) 0.000
Platelet x 109/Lt 17 (3–85) 31.5 (6–248) 0.006
RT-PCR - - -
bcr1 59 (60.2) 21(75) 0.311
bcr2 2 (2) 0
bcr3 37 (37.8) 7 (25)
Lactate dehydrogenase (IU/Lt)) 748 (291–2700) 554 (284–1155) 0.006
Fibrinogen (mg/dl) 161 (25–689) 163 (70–1122) 0.975
Additional CTG finding - - -
Yes 34 (36.6) 11 (61.1) 0.068
No 59 (63.4) 7 (38.9)
IC Bleed (at diagnosis or during induction
therapy)
- - -
Yes 16 (16.3) 0 0.022
No 82 (83.7) 28 (100)
Differentiation syndrome (during induction
therapy)
- - -
Yes 13 (13.3) 2 (7.11) 0.518
No 85 (86.7) 26 (92.9)
Blood product utilization induction - - -
PRC^ units 24 (0–85) 16 (0–48) 0.027
FFP* units 12 (0–72) 7 (0–60) 0.156
Cryoprecipitate units 6 (0–59) 3 (0–30) 0.456
^ PRC = platelet rich concentrate
*FFP = Fresh frozen plasma
doi:10.1371/journal.pone.0121912.t001
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different. The median IC50 value between the two groups was 4.41μM vs. 3.51μM (P = 0.29; Fig
3). These in-vitro values did not correlate with clinical parameters such as relapse, EFS or OS.
Cytogenetic and genetic analysis
There were both gain and loss of CTG aberrations in RAPL. There was also a trend to an in-
crease number of additional CTG aberrations in the relapsed group. Detailed analysis of the
CTG data is given in the supplementary information file (Results section and Table A in S1
File).
As ATO targets the B2 domain of PML and resistance to ATO has been attributed to B2 do-
main PML gene mutations, we performed Targeted Ion PGM sequencing of the PML B2 do-
main in 22 out the 26 NAPL cases and in all 26 RAPL cases in whom an adequate library for
subsequent sequencing could be obtained. Overall an average of 96.29% genome base coverage
was obtained at 100x depth. None of the NAPL cases had any mutations observed in the PML
B2 domain. In 4 (15.38%) of RAPL cases at least one mutation was observed in the B2 domain
of the PML allele involved in the fusion gene, all of them were novel. The frequencies of the
mutations and their function are summarized in Table 2. The absence of mutations was further
confirmed by Sanger sequencing.
The differential expression profile of 8 NAPL and 8 RAPL were generated. The data was
normalized with three different normalization methods (S1 File: Results C) and found to be
similar with good correlation. The pattern of differentially expressed genes obtained was robust
and similar with all the three normalization strategies. The overview of the gene clustering and
the differential expression profile is shown in Fig 4 and in supplementary information (S1 File:
additional excel sheet: S1 Dataset). In total, 1744 genes were> 2 fold differentially regulated
Fig 1. Comparison of bonemarrow blast immunophenotypic surfacemarker expression percentage between newly diagnosed and relapsed
patients. The percentage expression of common APL surface markers like CD13, CD33, CD34, CD38, VLA4 and VLA5 are illustrated as grouped bar
graphs for newly diagnosed (black bars) and at relapse (grey bars). The mean±SEM were significantly different for CD13, CD34 and CD38 between the
newly diagnosed and relapsed patients.
doi:10.1371/journal.pone.0121912.g001
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between the NAPL and the RAPL group which was 8.72% of the 20,000 genes in the array. Of
these 864 genes were up regulated while 880 genes were down regulated. The differentially ex-
pressed genes were categorized based on biological process, cellular component and molecular
function into biological functional groups based on the gene ontologies using Gene Spring and
Biointerpretor software (Agilent technologies). Important biological pathways over repre-
sented among the differentially expressed genes between the NAPL and RAPL are shown in
Table 3 (and Figure C in S1 File).
The prominent functional processes differentially regulated in relapsed patients were (i)
Cell adhesion: Integrins, Cadherins and Mucins, (ii) Cell survival and anti apoptosis: PI3-AKT,
PTEN, NFĸB, MAPK and JAK-STAT, (iii) Stem cell regulation: Wnt, Hedgehog and CD34,
(iv) Immune regulation: TNF-receptor super family genes, Interleukins. The complete gene list
in each of these pathways is given in the supplementary files (additional excel sheet: S2 Data-
set). The heat maps of these functional categories of representative genes in each pathway
which are differentially regulated between diagnosis and relapse in APL are shown in Figure D
in the S1 File. To validate the reliability of the data, 25 randomly selected genes were analyzed
by RQ-PCR and the results were highly concordant with the array data (Figure E in the S1
File).
Fig 2. Intracellular arsenic levels in malignant promyelocytes of APL patients at diagnosis, relapse, in
normal bonemarrowmononuclear cells (BMMNC) and in NB4 cell lines. Scatter plot of the intracellular
concentration of arsenic levels in newly diagnosed patients (N = 61) and relapsed patients (N = 19). The level
of arsenic is expressed as nanograms (ng) of arsenic detected in 107 cells after 24 hr culture with 0.5uM ATO.
Each value was mean of triplicates. There was no significant difference between the median values between
the two groups. ATO resistant NB4 cell line NB4-EV-AsR1 (n = 6) had a median ICATO value of 53.7 ng/107
cells, while that of NB4 (n = 5) cells was 65.1 ng/107 cells.
doi:10.1371/journal.pone.0121912.g002
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To verify the reproducibility of the microarray array data obtained from the pilot experi-
ment of 8 unmatched samples at diagnosis and relapse, we did RQ-PCR analysis of the same 25
random genes from the differential regulation list in a fresh set of 10 paired diagnostic and re-
lapse samples. The median fold difference in the expression level of these 25 genes between the
paired diagnosis/relapse was compared to that of the differential expression pattern obtained
in the microarray. 18/25 genes were differentially regulated in the same direction as predicted
by the microarray data (Figure F in the S1 File).
Comparison of the Effect of Stromal Cell and Malignant Promyelocyte
Interaction on the Apoptotic Action of ATO
Based on the microarray data and the prominent up-regulation of genes involved in cell adhe-
sion in RAPL compared to NAPL we evaluated the effect of co-culture of primary APL cells
from the NAPL and RAPL groups with MSCs and HS-5 (stromal cell line) on ATO sensitivity.
Fig 3. Comparison of in vitro cytotoxicity with ATO of NAPL Vs. RAPL and other cell lines. Scatter plots of the IC50 values of newly diagnosed patients
(N = 61) and relapsed patients (N = 23) after treating with ATO concentrations ranging from 0.1 to 6 μM for 48 hours is shown. The median IC50 of the newly
diagnosed (4.41 μM) and relapse group (3.51 μM) was not significantly different and was higher when compared to that of NB4 cell line (N = 16). The median
IC50 of NB4 was 0.9 μM, while that of NB4-EV-AsR1 (ATO resistant NB4 cell line) was 3.25 μM. The IC50 of HL60 was 4.25 μM.
doi:10.1371/journal.pone.0121912.g003
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Fig 4. Differential gene expression profile of relapsed Vs. newly diagnosed patients with Acute Promyelocytic Leukemia. The expression profile of
eight unmatched relapsed versus newly diagnosed acute promyelocytic leukemia samples. The cluster diagram represents> 2 fold significantly differential
gene list of 864 up regulated (red) and 880 down regulated genes (green). The ratios are color coded as indicated in the bar. The complete gene list and
annotations are given in the supplementary section (S1 Dataset).
doi:10.1371/journal.pone.0121912.g004
Table 3. Differentially regulated genes in relapsed cases classified into biological functional groups
based on the gene ontologies using Gene Spring and Biointerpretor software (Agilent Technologies).
Functional Groups Total number of genes upregulated Total number of genes downregulated
Adhesion 71 21
Tight junction 7 1
Stem cell 35 8
Apoptosis 41 11
Immune 50 24
Ion Channel 9 4
Ubiquitin 23 5
The table gives the number of genes and the direction of dysregulation in each of those biological functions
in the RAPL compared to the NAPL.
doi:10.1371/journal.pone.0121912.t003
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We noted a significant protective effect against the apoptotic action of ATO in both groups.
The median viability percentage of the NAPL at 4 μM concentration of ATO after 48 hours
was 64.34% when grown without MSC which increased to 91.76% when co-cultured with
MSCs (N = 32) (0.0003). At the same concentration of 4 μMATO the median viability percent-
age of RAPL was 64.81% when grown without MSC, while the median percentage was 96.12%
when co-cultured with MSCs (N = 12) (P = 0.024) (Fig 5). The gain in viability was not signifi-
cantly different between NAPL and RAPL patients studied (median viability gain in co-culture
21.30 Vs. 24.18 respectively; P = 0.96). A similar protective effect was not seen when malignant
promyelocytes were co-cultured with HUVEC cell lines (data not shown).
Similar to the APL primary cells, the protective effect was observed in the co-culture of NB4
cells with MSCs and HS-5 (n = 8; P = 0.02) (Figure G in the S1 File). Blocking antibodies against
VLA-4 and VLA-5 did not affect the protective effect of stromal cells on NB4 cells (data not
shown). There were no significant changes in the surface marker expression of the VLA4, VLA5,
CD184, CD44, CD123 and CD34 in either primary cells or NB4 cells on co-culture with HS-5
cells for 48 hours. The proliferation assay using CFSE staining in the presence of HS-5 showed a
significant reduction in the proliferation of NB4 cells in co-culture when compared to NB4 cells
alone at 48 and 72 Hrs respectively (N = 3; P = 0.003 at 48H) (Figure H in the S1 File). Cell cycle
analysis at 48 hours co-culture of NB4 with HS-5 cell line showed that there was a significant in-
crease in the percentage of G0/G1 cells from 48% to 62% (n = 6; P = 0.004) on co-culture when
compared to the NB4 cells alone (Figure H in the S1 File).
Discussion
While ATO is effective in inducing molecular remissions in the majority of patients with RAPL
the risk of relapse is high especially in the absence of consolidation with an autologous SCT
[13]. Having noted the inferior clinical response in patients with RAPL in comparison to
NAPL we wanted to evaluate the potential mechanisms to explain this difference.
Recent interest has focused on mutations in the oncogenic PML-RARA gene, especially mu-
tations in the B2domian of the PML component, which can result in acquired resistance to
ATO[18]. However, majority of patients who do relapse after treatment with ATO based
Fig 5. Impact of in vitro environment mediated (stromal cell co-culture) interaction on effect of ATO sensitivity at diagnosis and in relapsed cases.
The bar graph shows the mean viability percentage of the newly diagnosed [A] and relapsed [B] patients primary cells when cultured with or without stromal
cells (MSCs) and at varying concentrations of ATO incubated for 48 hours prior to apoptosis assay. There is a significant protective effect on primary cells in
both groups by MSC co-culture to ATO induced apoptosis.
doi:10.1371/journal.pone.0121912.g005
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regimens do not have such mutations[19] and additionally primary or secondary drug resis-
tance to ATO is rare in the clinic. The majority of RAPL patients achieve hematological and
molecular remissions even after multiple relapses on treatment with ATO though the duration
of response decreases and the risk of disease recurrence increase with each such relapse. Clonal
evolution with mutations leading to ATO resistance cannot explain the observations seen in
the clinic in the majority of patients.
At the time of diagnosis it was interesting to note that relapsed patients had a significantly
lower WBC count and significantly higher platelet count. It was also of interest to note that in
this prospective study there were a significantly lower number of IC bleeds and lower utiliza-
tion of platelet concentrates during induction therapy in relapsed cases suggesting that coagu-
lopathy was probably less severe in this group.
There was earlier data to suggest that malignant promyelocytes were able to better concentrate
ATO intracellularly than other malignant cells[24] and recent studies to suggest that there were
ABC transporters involved in ATO efflux[25]. We had hypothesized that in relapsed patients
such efflux mechanisms were probably involved and contributed to the increased relapse in these
patients. However, in this study we could not demonstrate any difference in the ability to concen-
trate ATO intracellularly between newly diagnosed and relapsed cases nor could we find any as-
sociation with these values and subsequent relapses. Consistent with these observations the GEP
data did not demonstrate differential expression of any of the known transporters involved with
ATO in these two cohorts. Similarly there was no difference in the in-vitro sensitivity of malig-
nant promyelocytes to ATO in both groups and no correlation with subsequent clinical events.
This data is consistent with the clinical observation that primary or secondary resistance to ATO
is very rare in patients. The previously reported PML B2 domain A216V ATO resistant mutation
[18] was not detected in any of the patients in this series. Of the 4 patients in this series that had
PML B2 domain mutations two achieved molecular remission with ATO based regimens. Of the
remaining two, one patient died in induction and one patient was discharged against medical ad-
vice however even in these two patients the in-vitro IC-50 data suggests that the blasts were sen-
sitive to ATO (IC50 below median value).
The GEP pattern of increased expression early HSC markers such as CD34 and decreased
expression of mature markers such as CD13, CD38 and CD44 in the relapsed group along with
increased expression of other genes in the stem cell pathway (n = 51) suggests that there could
potentially be a shift to a more immature phenotype and a potential expansion in the leukemia
initiating compartment in the RAPL patients. The IPT data validates GEP data by demonstrat-
ing a similar increased CD34 and reduced CD38 expression in RAPL. While there is limited
data on the phenotype of the stem cell / leukemia initiating compartment in human APL there
is some data to suggest that this population, at least in a mouse model, resides in promyelocytes
that are CD34(+), c-kit(+)and FcgammaRIII/II(+)[26, 27].
Based on the prominent up regulation in the GEP of adhesion and cytokine genes / path-
ways, previously reported to be involved in micro environment mediated drug resistance
(EM-DR) in other malignancies, in the RAPL cohort we further evaluated this with in-vitro ex-
periments. This is the first study to demonstrate innate EM-DR to ATO in APL leukemic cells
which is seen in both cell lines and primary cells. This innate EM-DR was marginally more
prominent in relapsed cases though this did not achieve statistically significant difference. The
exact mediators and mechanism needs further evaluation but our preliminary data suggests
that the co-culture induces quiescence that could potentially contribute to ATO resistance.
Though there are previous studies reporting GEP of APL patients at diagnosis, there are
none reporting the molecular gene expression signature of patients at the time of relapse fol-
lowing treatment with ATO. Even though we had a limitation of comparing unmatched sam-
ples at diagnosis and at relapse, the fact that the expression signature was subsequently
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validated in a fresh cohort of 10 paired diagnosis/relapse patient samples gives us the confi-
dence to pursue the pathways and genes picked up by microarray study to understand the dis-
ease progression. The major pathways and genes that are differentially expressed in relapsed
cases and the potential role played by them in relapse is summarized in the
supplementary section.
From this data we conclude that recurrent relapse in RAPL to ATO based therapy is proba-
bly multi-factorial. In APL clonal evolution resulting in by acquisition of mutations leading to
ATO resistance (such as the recently reported PML B2 domain mutation) are rare as is demon-
strated by the few cases in which this has been reported [18, 19] and the ability of ATO to in-
duce molecular remission in the majority of patients with multiple relapses even after prior
exposure to ATO. Based on our observations we hypothesize that contributory factors to re-
lapse in APL following treatment with ATO could include the expansion of the leukemia initi-
ating compartment and an increase in EM-DR to ATO (Figure I in the S1 File). Both these
mechanisms need further evaluation and additional experiments to validate these findings and
understand their molecular basis.
The microarray data discussed in this manuscript have been deposited in the NCBI Gene
Expression Omnibus (GEO) under the GEO series accession number GSE42030 and
GSE42031.
Supporting Information
S1 Dataset. Excel sheet with a list of genes that were differentially expressed when compar-
ing newly diagnosed and relapsed patient samples. All genes with> 2 fold differential ex-
pression in relapsed patients samples in comparison to newly diagnosed cases are included in
this list.
(XLSX)
S2 Dataset. Excel sheet with complete gene list arranged according to pathways that differ-
entially regulated. Complete gene list in the pathways that were differentially regulated in re-
lapse in comparison to newly diagnosed APL patients on a microarray gene expression profile.
(XLSX)
S1 File. Figure A. In vitro cytotoxicity of cell lines and primary cells to ATO. The mean
IC50 of HL60 cell line was 4.25uM (which is equivalent to the log concentration of ATO of 3.6
as represented in the above graph) [B]. There was negligible cell kill of the other cells checked
like the PBMNCs [A], MSCs [C] and U937 [D] at the concentrations of ATO used in this
study. All the experiments were reported as an average of at least 3 independent experiments.
Figure B. Comparison of the Median Fluorescent Intensity of bone marrow blast immunophe-
notype markers in newly diagnosed vs. relapsed patients. The median fluorescent intensity
(MFI) values of the immunophenotypic markers of the patients in the newly diagnosed and re-
lapsed group are represented as individual stick bars. Figure C. Differentially regulated genes in
relapsed cases classified into biological functional groups based on the gene ontologies using
Gene Spring and Biointerpretor software. The genes differentially up regulated [A] and down
regulated [B] in relapse group when compared to newly diagnosed group are fit into biological
functions based on their gene ontologies using the Biointerpretor software (Agilent Technolo-
gies). [C] The table gives the number of genes and the direction of dysregulation in each of
those biological functions. Figure D. Heat maps of differentially regulated genes in functional
pathways. Heat map demonstrating the genes up regulated (red) and down regulated (green) at
least 2 fold in relapse (REL) in comparison to at diagnosis (DX) classified in functional catego-
ries. The ratios are color coded as indicated in the bar. Figure E. Validation of the gene
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expression differential regulation using RQ-PCR- ΔΔCT method. Comparison of RQ-PCR
data of 25 genes from the same set of samples from which the microarray data was derived.
Median fold difference was calculated by ΔΔCT method. Individual cases values are average of
triplicates. Concordant results were obtained in all but four genes as illustrated. Figure F. Vali-
dation of a set of microarray predicted gene expression in a second cohort of paired matched
samples (n = 10) that were available both at diagnosis and at relapse. The bar graph shows the
comparison between the relative fold difference in the selected 25 genes between the initial di-
agnosis and at the subsequent relapse of 10 patients. 18 of the 25 genes evaluated by RQ-PCR
in these cases had the regulation altered in the same direction as predicted by the microarray
data from the initial cohort. Figure G. Protective effect of stromal cell co-culture of NB4 cells
against ATO. The bar graph shows the mean viability percentage of the NB4 cells when cul-
tured with or without stromal cells (MSCs) and at varying concentrations of ATO incubated
for 48 hours prior to apoptosis assay. There is a significant protective effect in NB4 cells by
MSC co-culture to ATO induced apoptosis (N = 9). Figure H. Effect of stromal cell interaction
on cell cycle and cell proliferation assay on NB4 cells in the stromal cell co-culture system. [A]
Cell cycle analysis NB4 cells with and without co-culture with HS-5 cells for 48H stained with
PI [B]. The NB4 cells were stained with CFSE and cultured with and without HS-5 cells, for 24,
48 and 72 hours respectively. Figure I. Model of ATO resistance based on our observations in
this study.
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